Windward Bio IPO plans moved forward on October 23, 2026, when the Swiss clinical-stage biotechnology company filed for a U.S. initial public offering. Windward Bio Group AG is seeking to list common shares on the Nasdaq Global Market under WWB, but has not disclosed the number of shares or an expected price range.
Key Takeaways
- The filing starts a proposed offering process; Nasdaq approval and completion remain pending.
- Windward Bio has raised up to $365 million through equity financings since its founding in 2024.
- The company develops ultra-long-acting antibodies for respiratory and dermatologic diseases.
Table of Contents
- Windward Bio IPO terms remain open
- Healthcare investors backed earlier financing
- Antibody pipeline targets less frequent dosing
- Conclusion
Windward Bio IPO terms remain open
The company’s F-1 registration statement says no public market currently exists for its common shares. The proposed offering cannot proceed until the registration statement becomes effective, and Windward says it will not complete the deal if its Nasdaq listing application is not approved.
Without a share count or price range, the filing does not establish how much the IPO would raise or the valuation at which investors would buy shares. Jefferies, TD Cowen, Piper Sandler and UBS Investment Bank are named on the preliminary prospectus.
| Item | Details |
|---|---|
| Filing date | October 23, 2026 |
| Proposed listing | Nasdaq Global Market; ticker WWB |
| Offering size | Share count and expected price range not disclosed |
Healthcare investors backed earlier financing
Founded in 2024, Windward Bio has secured up to $365 million through equity financings backed by investors including OrbiMed, Novo Holdings, SR One, Omega Funds, Blue Owl Healthcare Opportunities and RTW Investments.
That financing figure relates to funding before the proposed public offering, not expected IPO proceeds. The company is headquartered in Basel, Switzerland, and maintains U.S. operations.
Antibody pipeline targets less frequent dosing
Windward is developing antibody medicines for asthma, chronic obstructive pulmonary disease and atopic dermatitis. Its candidates are engineered to remain in the body for extended periods, with the aim of reducing dosing frequency compared with currently available treatments.
Its WIN378 candidate is being evaluated in POLARIS-1, a Phase 2/3 study in severe uncontrolled asthma. The Phase 3 portion began in September 2026. A separate Phase 2 study in COPD, SIRIUS, began in June 2026.
Start-up activities for a second Phase 3 asthma study, POLARIS-2, began in September 2026, with patient recruitment planned for the first half of 2027. That recruitment timetable remains a company plan rather than a completed milestone.
Conclusion
The Windward Bio IPO remains an unpriced proposal, not a completed listing. The next offering details to watch are the share count and price range; neither had been set in the October 23 filing.
Read More News
Disclaimer
This FinanceVelix article provides general information, not personalized financial, investment, legal, or tax advice. Market prices, interest rates and economic conditions can change; investments carry a risk of loss. Facts reflect the material available when published and may change. Check important information independently and consult a qualified professional when needed. Mentioning an asset, company, or service is not an endorsement.
